Prospective Study
Copyright ©The Author(s) 2016.
World J Hepatol. Jul 8, 2016; 8(19): 815-824
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.815
Table 1 Characteristics of the population at baseline n (%)
Patients’ characteristicsOverall population (n = 48)Patients treated with DAAs (n = 8)
Qualitative variables
Gender
Female25 (52)1 (12)
Male23 (48)7 (88)
HCV RNA genotype
1a3 (6)0 (0)
1b29 (61)8 (100)
2a/2c4 (8)0 (0)
31 (2)0 (0)
42 (4)0 (0)
Not available9 (19)0 (0)
Quantitative variables, median (range)
Age (yr)67.0 (36.0-84.0)63.5 (51.0-69.0)
eGFR (mL/min)90.0 (30.0-111.7)93.0 (77.0-109.0)
FIB-43.0 (0.5-18.3)3.7 (1.5-9.0)
AST (IU/L)44.0 (17.0-180.0)70.0 (28.0-103.0)
ALT (IU/L)45.0 (12.0-268.0)53.5 (35.0-171.0)
Albumin (mg/dL)4.2 (3.0-4.8)4.3 (3.3-4.6)
Total bilirubin (mg/dL)0.8 (0.3-2.2)0.6 (0.3-1.0)
PLT (n/μL)141000 (13500-312000)132000 (71000-229000)
WBC (cells/μL)5560 (2220-11500)6245 (2790-9200)
HCV-RNA (copies/mL)776500 (90100-19500000)2330000 (793000-3250000)

  • Citation: Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824
  • URL: https://www.wjgnet.com/1948-5182/full/v8/i19/815.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v8.i19.815